Searched for
SYNGENE STOCK
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...- LIC dividend alert! Last day to buy insurance behemoth’s shares for Rs 10 dividendLIC has fixed June 25 as the record date for its Rs 10 final dividend, making today the last opportunity for investors to buy shares to qua...
- Dividends & bonus issues: LIC, Asian Paints among 35 stocks turning ex-record date this week. How many do you own?Around 35 companies, including LIC, HUL, Asian Paints and IndusInd Bank, have fixed record dates for dividends, bonus issues and buybacks i...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian equities ended sharply lower as weak global cues and geopolitical tensions triggered broad-based selling. Nifty slipped 1.04% to 23,...
- Two Trades for Today: A biopharma firm for a 7.65% rise, a mid-cap healthcare stock for an upmove of about 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Biocon shares rise 1% after billionaire Kiran Mazumdar-Shaw names niece as successorBiocon's chairperson, Kiran Mazumdar-Shaw, has named her niece, Claire Mazumdar, as her successor, sparking a more than 1% jump in the comp...
- Smallcap winners! Wockhardt, Tata Tech, CAMS, other stocks rally up to 11% despite overall market weaknessSmallcap stocks outperformed on Tuesday despite weak broader markets, with Wockhardt, Tata Tech and CAMS gaining up to 11% on strong Q4 ear...
- Ahead of Market: 10 things that will decide stock market action on MondayIndian stock markets experienced sharp cuts on Thursday, with Nifty and Sensex declining due to rising oil prices and a falling rupee. Sell...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Stock Radar: Syngene International showing signs of momentum after falling 26% from highs; what should investors do?Syngene International stock is showing positive signs. The stock has recovered after hitting a 52-week low. It is trading above several key...
- Buy Syngene International, target price Rs 880: IIFLPromoters held 54.8 per cent stake in the company as of 30-Jun-2023, while FIIs owned 23.19 per cent, DIIs 11.2 per cent.
- Stock Radar: Breakout from Descending Channel could take this healthcare stock to fresh record highsWhile the stock has failed to hold its record high and is considered to be overbought, it's still viewed as a profitable investment as it h...
- Buy Syngene International, target price Rs 642 : HDFC SecuritiesDaily RSI is in an attempt of moving above 60 levelsand volume has started to expand during upmove.
- Syngene can put on muscle as global pharma companies increase R&D spendingSyngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.
- Syngene International makes stellar debut, ends day up 24% over issue priceIt hit an intraday high of Rs 318.20 over its issue price, before settling the day at Rs 310.40, up 24.16 per cent on the BSE.
- Is it time to book profits on Biocon counter post Syngene listing?Biocon has gained nearly 9 per cent in the past six months, compared to a 2 per cent fall in the BSE benchmark Sensex.
- Syngene gets FIPB nod to raise foreign investment to 44%Syngene, a subsidiary of Biocon, said it has received the Foreign Investment Promotion Board approval to raise foreign investment to 44 per...
- Syngene dragged too far as value proposition; avoid Biocon: Prakash DiwanWhile Syngene has a healthy pipeline of biosimilars, the monetisation of some of the molecules could take up to six years, says Diwan.
- Biocon unit inks pact with US firm to expand collaborationBiotech firm Biocon today said its subsidiary 'Syngene International' has entered into an agreement with US-based Endo Pharmaceuticals to e...
Load More
